Marcos Timón Spanish Medicines Agency (AEMPS)

Marcos Timón

Marcos Timón Spanish Medicines Agency (AEMPS)

Marcos Timon is Head of Unit at the Division of Biological Products, Advanced Therapies and Biotechnology within the Spanish Medicines Agency (AEMPS). He is the alternate member for Spain at the Committee for Advanced Therapies (CAT) and member of the Quality Innovation Group (QIG).

After completing his PhD in Spain, Marcos moved to London to work as a postdoctoral scientist at the Tumour Immunology Unit of the Imperial Cancer Research Fund (now Cancer Research UK). He continued his research activities first at the Department of Oncology (University College London) and later at the Edward Jenner Institute for Vaccine Research, also in the UK. He then moved back to Spain to work as Chief Scientific Officer at Mologen Molecular Medicines, a subsidiary of Mologen AG (a biotech company based in Berlin, Germany).

Since joining AEMPS, he has been mostly involved in the quality assessment of medicinal products of biological origin, including Cell and Gene Therapy Medicinal Products.

Apart from attending the CAT and QIG, Marcos is also a member of the WHO Expert Advisory Panel on INN for Advanced Therapies and of other expert groups at national and international level. He was also a member of the Biologics Working Party from 2016 to 2022.